X4 Pharmaceuticals (XFOR) Liabilities and Shareholders Equity (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Liabilities and Shareholders Equity for 10 consecutive years, with $253.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 140.63% year-over-year to $253.1 million; the trailing twelve-month figure through Jun 2026 stood at $977.4 million (up 74.59% YoY), and the FY2025 full-year result was $290.5 million, up 98.34% from the prior year.
• Liabilities and Shareholders Equity slipped to $253.1 million in Q2 2026 per XFOR's latest filing, from $270.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $290.5 million in Q4 2025 and bottomed at $81.0 million in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $162.7 million across 5 years, with a median of $151.4 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity sank 50.07% in 2025, then jumped 140.63% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $155.6 million in 2022, then slipped by 5.35% to $147.3 million in 2023, then slipped by 0.55% to $146.4 million in 2024, then soared by 98.34% to $290.5 million in 2025, then declined by 12.88% to $253.1 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $253.1 million, $270.3 million, and $290.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.